Literature DB >> 17039659

Etanercept responsive acrodermatitis continua of Hallopeau: is a pattern developing?

Brian Bonish1, Rashid M Rashid, James Swan.   

Abstract

Acrodermatitis continua of Hallopeau (ACH) is a rare disease. Little is known about its etiology or relative effectiveness of the various therapeutic approaches. However, in the literature a pattern seems to be developing on successfully treated patients using biologic therapies. Here, we further emphasize the potential breakthrough presented by the novel immune based therapies. This report consists of a case of etanercept responsive ACH along with a brief review of the literature.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17039659

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  3 in total

Review 1.  Autoinflammatory pustular neutrophilic diseases.

Authors:  Haley B Naik; Edward W Cowen
Journal:  Dermatol Clin       Date:  2013-06-02       Impact factor: 3.478

2.  Acrodermatitis continua of hallopeau successfully treated with adalimumab.

Authors:  Jennifer A Sopkovich; Georgann Anetakis Poulos; Henry K Wong
Journal:  J Clin Aesthet Dermatol       Date:  2012-02

3.  Acrodermatitis continua of Hallopeau: clinical perspectives.

Authors:  Mary Patricia Smith; Karen Ly; Quinn Thibodeaux; Tina Bhutani; Wilson Liao; Kristen M Beck
Journal:  Psoriasis (Auckl)       Date:  2019-08-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.